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ABSTRACT
The pneumococcal seven-valent conjugate vaccine (PCV7) has been administered in Portugal since late
2001 through the private sector. To evaluate the impact of PCV7 use, the serotypes and antimicrobial
susceptibility of pneumococci causing invasive disease in Portugal during 2003–2005 were determined
and compared with available data for the period 1999–2002. Changes in serotype distribution compatible
with the introduction of PCV7 were shown for children £5 years of age from 2003 onwards and for adults
from 2004 onwards. PCV7 use with coverage of 43% of children with four doses in the 2004 birth cohort,
although substantially below universal coverage, seems to have contributed to greatly reducing the
proportion of invasive infections due to vaccine serotypes 4, 6B, 14 and 23F. Similarly, significant indirect
effects on the serotype distribution of pneumococci causing infections in adults were noted, with
reductions in the proportion of invasive infections caused by serotypes 4, 5 and 14. These changes were
accompanied by an increase in the proportion of two non-vaccine serotypes: 19A isolates in all age groups
and 7F isolates in adults. Whereas serotypes 6B, 14 and 19A were associated with multidrug resistance,
isolates expressing serotypes 4 and 7F were fully susceptible for the most part. There were no changes in
the proportion of resistant isolates within each serotype and, in spite of the changes in serotype prevalence,
there was not an overall reduction in the proportion of infections caused by resistant pneumococci.
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INTRODUCTION
In early 2000, the seven-valent pneumococcal
conjugate vaccine (PCV7; includes serotypes 4,
6B, 9V, 14, 18C, 19F, 23F) was licensed in the USA,
and this was followed shortly after by recom-
mendations for the universal vaccination of
infants and children under 2 years of age [1]. In
the European Union, the vaccine was only
licensed 1 year later, in February 2001, and actual
availability in individual countries may still have
required approval by the national regulatory
agencies [2]. In contrast to the USA, availability
was not followed shortly after by recommenda-
tions for universal vaccination. By 2003, most
European countries had issued vaccination rec-
ommendations for risk groups only, although the
definition of these groups varied widely among
countries and could be highly targeted or include
large portions of the paediatric population [3].
This situation started changing in 2005, and by
January 2007, ten countries, including the UK,
France and Germany, had adopted universal
vaccination plans [2].
Studies in the USA, following vaccine intro-
duction, showed a dramatic impact on the num-
ber of cases of invasive infections as well as on the
distribution of the serotypes causing disease, the
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burden of disease caused by the vaccine serotypes
being greatly reduced [1]. This decrease was
observed not only in the children targeted for
vaccination but also in adults, including the
elderly, who have a high burden of pneumococcal
disease. In fact, the largest number of cases of
invasive pneumococcal disease prevented by
vaccination is not among the population targeted
by vaccination but among the elderly, as a
consequence of herd immunity [4]. Moreover,
results from other studies indicate that the
vaccine also had an impact on non-invasive
infections by reducing the cases of otitis media
due to isolates of vaccine serotypes [5], by
reducing the cases of radiologically confirmed
pneumonia [6], as well as by reducing the inci-
dence of antimicrobial-resistant pneumococcal
invasive infections [7]. However, the overall
decrease in the burden of pneumococcal invasive
disease was accompanied by an increase in the
number of cases caused by non-vaccine serotypes
[5] and, in particular, the emergence of sero-
type 19A as an increasingly important cause of
invasive infections in all age groups in the USA
[8]. For unknown reasons that may be related to
higher exposure, carriage rates or host suscepti-
bility, these changes have been faster to occur and
more apparent among some populations than
others, as was recently demonstrated by a study
of the Alaskan native population that was specif-
ically targeted for vaccination [9].
It has been argued that pneumococcal invasive
disease differs between western Europe and the
USA in its incidence, which seems to be lower in
Europe [10], although this finding has been
questioned because of different cultural practices
[11]. The prevalence of the serotypes found
among invasive infections also varies between
the two regions, and this affects the potential
coverage of PCV7, due to the limited number of
serotypes included in the vaccine. Vaccine cover-
age for invasive pneumococcal infections in
children £5 years of age, estimated from the
distribution of serotypes, varies from 53.8% in a
Spanish study to 85% in Denmark [12], but is
mostly below that estimated for the USA [13]. It
remains to be shown whether the consequences of
vaccination documented in the USA are due to
the particular structure of the circulating pneu-
mococcal population and whether they will be
replicated in the European countries where
universal vaccination was adopted.
The situation in countries where the vaccine is
available but not universally administered, such as
Italy [2], Spain (http://www.msc.es/ciudadanos/
proteccionSalud/infancia/docs/neumo.pdf) and
Portugal, is even more complex. In spite of the
unquestioned efficacy of PCV7 in preventing
invasive infections by vaccine serotypes among
vaccinees [6], depending on the fraction of
vaccinated children, one might expect a variable
magnitude of reduction of the infections caused
by vaccine serotypes in the overall paediatric
population, and also the existence and scope of
indirect effects on infections in adults. In Portu-
gal, PCV7 has been available since June 2001,
and although it is not currently included in the
National Vaccination Plan, it has been adminis-
tered to children through the private sector
without government funding. By 2002, c. 33%
of the children up to 3 years of age had received
at least one dose of PCV7, mostly after
23 months of age [14]. More recently, a survey
was conducted using a methodology that in-
volves direct evaluation of vaccination records
and that was previously shown to provide
highly reliable vaccination estimates [15]. In this
study, the vaccination records of approximately
one-third of all children born in Portugal
between 2001 and 2005 were evaluated, taking
into account the currently recommended PCV7
vaccination schedule in Portugal of three doses
and a booster administered at 2, 4, 6 and
18 months or at 3, 5, 7 and 18 months. The
proportion of children with three doses at
12 months of age increased steadily from 23.7%
in the cohort of birth in 2001 to 51.2% in the
2005 cohort, as did the proportion of children
with four doses at 24 months, which increased
from 20.2% in the 2001 cohort to 43.1% in the
2004 cohort (data from the 2005 cohort were not
yet available) (Queiro´s et al., ‘Cobertura pela
vacina pneumoco´cica conjugada heptavalente
nas coortes de nascimento de 2001 a 2005 na
regia˜o norte’, available at: http://www.dgs.pt).
It has previously been shown that the distribu-
tion of serotypes of pneumococci causing inva-
sive infections were essentially stable until 2002
[16,17], establishing a baseline against which the
impact of vaccination could be evaluated. The
changes in the pneumococcal population causing
invasive disease in Portugal from 2003 to 2005
are reported here, with particular attention given
to the distribution of serotypes.
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MATERIALS AND METHODS
Bacterial isolates
Since 1999, the Portuguese Surveillance Group for the Study of
Respiratory Pathogens has monitored pneumococci causing
invasive infections in Portugal. This is a laboratory-based
surveillance system, in which 30 microbiology laboratories
throughout Portugal are asked to identify all isolates respon-
sible for invasive pneumococcal infections and to send them to
a central laboratory for characterization. A case of invasive
disease is defined by an isolate of Streptococcus pneumoniae
being recovered from a normally sterile body site and does not
include isolates recovered from the middle ear. Although the
laboratories were contacted periodically to submit the isolates
to the central laboratory, no audit was performed to ensure
compliance, which may be highly variable in this type of study
[18]. The isolates recovered up to 2002 were previously
characterized both phenotypically and genotypically [16,17].
Only one isolate from each patient was considered and,
whenever isolates from blood and cerebrospinal fluid (CSF)
were available, only the CSF isolate was considered.
Serotyping and antimicrobial susceptibility testing
Serotyping was performed by the standard capsular reaction
test using the chessboard system [19] and specific sera (Statens
Seruminstitut, Copenhagen, Denmark). Etest strips (AB Bio-
disk, Solna, Sweden) were used to determine the MICs of
penicillin, cefotaxime and levofloxacin, as previously
described [20], and the CLSI-recommended breakpoints [21]
were used to interpret MIC values. Isolates were further
characterized by determining their susceptibility to erythro-
mycin, clindamycin, vancomycin, linezolid, tetracycline,
trimethoprim–sulphamethoxazole and chloramphenicol by
the Kirby–Bauer disk diffusion technique, according to the
CLSI recommendations and interpretative criteria [21].
Statistical analysis
Unless otherwise stated, analyses were performed using the
information available for the entire period 1999–2005, taking
into consideration two age groups only: children £5 years of
age (n = 177) and adults (‡18 years, n = 1074), excluding the
group of individuals aged 6–17 years (n = 47). The former
group relates to current recommendations suggesting vacci-
nation of children aged £5 years who attend day-care centres
[22], and most children in Portugal in this age group are
indeed attending day-care centres. The adult population is not
vaccinated, and the group of individuals aged 6–17 years was
excluded, as it presented a low incidence of infections and
could include individuals vaccinated in an undefined catch-up
schedule as well as non-vaccinated individuals. A global
comparison of the yearly serotype distributions during the
period 1999–2005 was performed through the estimation of
mutual information. The value of the mutual information is a
measure of dependency (similarity) between two probability
distributions, expressing how much information is common to
the two distributions. The absolute minimal value of mutual
information is 0 and implies that the two distributions are
independent. In other words, as two distributions become
more similar, it becomes easier to predict one distribution by
knowing the other, and this corresponds to an increase in
mutual information [23]. This technique was used to identify a
breakpoint delimiting two periods when the serotype distri-
bution among invasive isolates changed most significantly. It
was previously shown that the pneumococcal population
causing invasive infections in Portugal was stable from 1999 to
2002 [16,17] in spite of the availability of PCV7 since June 2001.
In order to evaluate the potential impact of vaccination, the
breakpoint in time that maximizes the differences in serotype
distribution was estimated by determining the mutual infor-
mation between the distributions for every possible breakpoint
year for two age groups: children £5 years of age and adults
(‡18 years).
The vaccine impact on serotype frequency was evaluated
by conditional relative risk (cRR) estimation and correspond-
ing 95% confidence intervals computed by the Wald method
[24]. The cRR was calculated relative to invasive infections
caused by particular serotypes among individuals in whom
invasive pneumococcal infections were detected. Individuals
were considered to have been exposed to vaccine effects if
the invasive infection occurred in the postbaseline period.
The expression used was cRR = (ne ⁄Ne) ⁄ (nb ⁄Nb), in which ne
is the number of isolates of a particular serotype or group of
serotypes in the post-vaccine period, Ne is the total number
of isolates in the post-vaccine period, nb is the number of
isolates of a particular serotype or group of serotypes in the
baseline period, and Nb is the total number of isolates in the
baseline period. Statistically significant differences in propor-
tions of resistant isolates and associations of serotypes with
particular resistant phenotypes were detected through the
two-tailed Fisher exact test [24]. When all individual
serotypes were simultaneously tested for association or for
differences in proportion, the resulting p-values were
corrected for multiple testing by keeping the false discovery
rate under or equal to 0.05 through the linear procedure of
Benjamini and Hochberg [25]. Other p-values indicated in
the text were considered to be significant if they were lower
than 0.05.
RESULTS
Isolate collection and capsular serotyping
An increase in the total number of isolates recov-
ered in each year was noted (n = 196 in 2003,
n = 256 in 2004, and n = 363 in 2005). From 2003 to
2005, 713 isolates (87.5%) were recovered from
blood, 47 (5.8%) from CSF, and 55 (6.7%) from
other normally sterile fluids. Forty-three isolates
(5.3%) were obtained from children below 2 years
of age, 47 (5.8%) from children 2–5 years of age, 32
(3.9%) from patients 6–17 years of age, and 693
(85.0%) from adults (‡18 years). All strains were
confirmed to be S. pneumoniae by colony morphol-
ogy and haemolysis on blood agar plates, optochin
sensitivity, and bile solubility.
The results of serotyping of the isolates recov-
ered from 2003 to 2005 are summarized in Fig. 1.
The minima in the mutual information curves
indicate the breakpoint years that reveal two time
periods whose serotype distributions are more
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divergent from each other (Fig. 2). The two age
groups considered showed minima in different
years. In the group of £5 year-olds, the breakpoint
occurs between 2002 and 2003, but when adults
are considered, the breakpoint occurs from 2003
to 2004. According to these breakpoints, from
among the cases of invasive pneumococcal infec-
tions, the cRR of the infection being caused by a
vaccine serotype after the breakpoint was esti-
mated, by comparing with the same risk before
the breakpoint. The conditional risk that invasive
infections are caused by vaccine serotypes in
children £5 years of age is reduced to half after
2002 (cRR = 0.50 (95% CI 0.35–0.74)). Such a
reduction was expected, as PCV7 use is protecting
vaccinees in this population from infections
caused by vaccine serotypes. A significant reduc-
tion in the adult population after 2003 (cRR = 0.72
(95% CI 0.58–0.88)) was also noted, indicating
that in this population also there were changes in
serotype distribution. These two different time
periods were therefore taken to define the base-
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Fig. 1. Cases of invasive pneumo-
coccal disease according to serotype
and age group in Portugal (2003–
2005). PCV7 indicates the serotypes
included in the seven-valent conju-
gate vaccine. 13Pv indicates the
serotypes included in the 13-valent
conjugate vaccine currently under
development.
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Fig. 2. Changes in serotype distribu-
tion (1999–2005). Minima in mutual
information graphs indicate the
years dividing the study into two
periods with maximally divergent
serotype distributions. (a) Analysis
concerning children £5 years of age.
(b) Analysis concerning adults
(‡18 years of age).
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line pneumococcal population and the population
after an effect of vaccination is noted in the two
age groups, and was used thereafter.
An analysis taking individual serotypes into
account showed that not all serotypes included in
PCV7 were significantly reduced after vaccine
introduction. In children £5 years of age, sero-
types 6B, 14 and 23F were reduced, whereas in
the adult population, serotypes 4 and 14 showed
a significant reduction in risk (Table 1). Among
non-vaccine serotypes, an increased relative risk
could be shown for the infections being caused by
serotype 19A in both children and adults, as well
as by serotype 7F, but only in adults, and a
reduced relative risk of the infection being caused
by serotype 5, also exclusively in adults.
Antimicrobial susceptibility
The results of antimicrobial susceptibility testing
are summarized in Table 2. The serotypes most
frequently found among resistant isolates are
shown in Table 3. These data from the years
2003–2005 were compared with data from an
earlier study from the baseline years (1999–2002
for children £5 years of age and 1999–2003 for
those subjects 18 years old [16,17]). Possible dif-
ferences in the prevalence of isolates resistant to
the antimicrobial agents tested between the base-
line and the period after vaccination when changes
were noted in the pneumococcal population were
evaluated (Fig. 2). Among children <6 years of
age, a significant decrease in penicillin-non-sus-
ceptible isolates was noted, from 44.8% in 1999–
2002 to 26.7% in 2003–2005 (p = 0.013). In contrast,
among adults, an increase in resistance was noted
between the periods 1999–2003 and 2004–2005 for
several antimicrobial agents: tetracycline resis-
tance increased from 7.7% to 12.2% (p = 0.014),
erythromycin resistance from 9.7% to 13.9%
(p = 0.037), and the proportion of isolates simul-
taneously resistant to erythromycin and non-sus-
ceptible to penicillin increased from 4.4% to 8.0%
Table 1. Changes in the conditional
relative risk (cRR) of invasive dis-
ease according to individual sero-
types Serotypesa
£5 years of age ‡18 years of age
1999–2002
(n = 87)
2003–2005
(n = 90)
cRR
(95% CI)
1999–2003
(n = 548)
2004–2005
(n = 526)
cRR
(95% CI)
PCV7
4 0 1 – 43 24 0.58 (0.36–0.94)
6B 8 1 0.12 (0.02–0.95) 9 5 0.58 (0.30–2.94)b
14 22 6 0.26 (0.11–0.62) 61 34 0.58 (0.39–0.87)
23F 15 6 0.39 (0.16–0.95) 10 11 1.15 (0.49–2.68)b
Others
5 1 1 0.97 (0.06–15.21)b 13 1 0.08 (0.01–0.61)
19A 5 22 4.25 (1.69–10.73) 21 40 1.98 (1.18–3.32)
7F 3 6 1.93 (0.50–7.49)b 21 42 2.08 (1.25–3.47)
aOnly serotypes presenting significant values in at least one of the age groups considered is indicated. Data from the
1999–2002 period were reported previously [17].
bcRR was not considered to be significant, as the 95% CI included 1.
Table 2. Antimicrobial susceptibility of isolates responsi-
ble for invasive infections (2003–2005)
No. of resistant isolates (%)
£5 years of age (n = 90) ‡6 years of age (n = 725)
PENRa 5 (5.6) 9 (1.2)
PENIa 19 (21.1) 108 (14.9)
CTXRb 1 (1.1) 0 (0.0)
CTXIb 3 (3.3) 8 (1.1)
LEV 0 (0.0) 1 (0.1)
ERYc 21 (23.3) 103 (14.2)
CLI 18 (20.0) 90 (12.4)
CHL 7 (7.8) 22 (3.0)
SXT 23 (25.6) 124 (17.1)
TET 17 (18.9) 87 (12.0)
VAN 0 (0.0) 0 (0.0)
LZD 0 (0.0) 0 (0.0)
PEN, penicillin; CTX, cefotaxime; LEV, levofloxacin; ERY, erythromycin; CLI,
clindamycin; CHL, chloramphenicol; SXT, trimethoprim–sulphamethoxazole; TET,
tetracycline; VAN, vancomycin; LZD, linezolid.
aPENR, penicillin-resistant; PENI, penicillin-intermediate. MIC range for all isolates
was 0.003–12 mg ⁄L, MIC50 = 0.016 mg ⁄L and MIC90 = 0.5 mg ⁄L.
bCTXR, cefotaxime-resistant; CTXI, cefotaxime-intermediate. MIC range for all
isolates was 0.004–4 mg ⁄L, MIC50 = 0.023 mg ⁄L and MIC90 = 0.5 mg ⁄L.
cThe majority of macrolide-resistant isolates (87%) presented the MLSB phenotype.
Table 3. Serotypes most frequently found among resistant
isolates (all ages 2003–2005)
Serotype
Fully
susceptible
No. of isolates resistant to:
At least one
antimicrobial
agent PENa ERY MDR
6B 2 9 6 (1) 9 9
9V 5 17 12 (2) 2 3
14 7 53 43 (4) 19 13
15A 1 9 9 (0) 9 9
19A 17 57 35 (4) 44 47
23F 4 21 18 (2) 3 5
Otherb 524 89 18 (1) 36 30
Total 560 255 141 (14) 126 116
PEN, penicillin; ERY, erythromycin; MDR, multidrug resistance (defined as
resistance to at least three antimicrobial classes).
aIsolates non-susceptible to penicillin are indicated. Numbers in parentheses
indicate fully resistant isolates (MIC ‡2 mg ⁄L).
bOther includes a total of 42 different serotypes and non-typeable isolates.
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(p = 0.016). These changes could be due to alter-
ations in the frequency of serotypes that are
associated with certain antimicrobial resistance
traits or to changes in the proportion of resistant
isolates within a particular serotype or group of
serotypes. To help distinguish between the contri-
butions of each of these factors, the association
between serotype and resistance for each of the
antimicrobial classes tested was analyzed for all
invasive isolates (Table 4). Serotypes 6B, 14 and
19A were significantly associated with resistance
to most antimicrobial agents, in contrast to sero-
types 1, 3, 4, 7F and 8, which were significantly
associated with susceptibility to most antibiotic
agents. Individually, none of the serotypes showed
a significant change in the proportion of non-
susceptible isolates between the two time periods,
for any of the antimicrobial agents, either in chil-
dren or in adults (two-tailed Fisher’s exact test).
These data indicate that the observed changes in
the fraction of resistant isolates are mainly due to
alterations in the relative proportions of the sero-
types associated with particular resistance traits
between the two periods.
DISCUSSION
Even non-universal vaccination with PCV7 has
the potential to greatly change the contribution of
the various serotypes to pneumococcal invasive
disease. This study design does not allow an
estimation of the incidence of pneumococcal
invasive infections and, therefore, a quantification
of the expected benefits of vaccination. A tempo-
ral trend towards more frequent blood culturing,
particularly in cases of community-acquired
pneumonia and bacteraemia without a focus,
which are traditionally infrequent in Europe
[10,18], was possibly a major factor behind the
increase in the number of isolates recovered each
year. The enhanced awareness of pneumococcal
invasive disease, due to the availability of PCV7
and to current debates regarding the use of the
23-valent polysaccharide vaccine in Europe, may
have enhanced compliance of the participating
laboratories, further compounding this trend.
This temporal trend would bias an estimate of
the incidence of invasive pneumococcal infec-
tions; we have therefore refrained from evaluat-
ing the impact of vaccination on the burden of
disease and have instead concentrated on changes
in the prevalence of the different serotypes in
invasive infections.
Similar to the herd effect documented in the
USA [4], indirect consequences of vaccination of
children were also noted in Portugal in the
serotype distribution of pneumococci causing
invasive infections among the adult population,
Table 4. Associations of resistance and serotype (all ages 1999–2005)
Antimicrobial resistance phenotypea
CHL SXT TET PEN CTX ERY PEN + ERY MDR
+ + ) + ) + ) + + ) + ) + )
Serotypes 1 1 1 1 1 1
3 3 3 3 3 3
4 4 4 4 4 4
6B 6B 6B 6B 6B 6B 6B
7F 7F 7F 7F 7F 7F
8 8 8
9V 9V
10A 10A
11A 12B
14 14 14 14 14 14
15A 12B 15A 15A
19A 19A 19A 19A
19A 19A
19F 22F
23F 19A 22F
18C
23F
33F 22F 33A
33F
CHL, chloramphenicol; SXT, trimethoprim–sulphamethoxazole; TET, tetracycline; PEN, penicillin; CTX, cefotaxime; ERY, erythromycin; MDR, multidrug resistance
(defined as resistance to at least three antimicrobial classes); +, a higher than expected proportion of isolates that were non-susceptible to that particular antimicrobial
among the serotypes indicated (a positive association with resistance); ), a lower than expected proportion of isolates that were non-susceptible to that particular
antimicrobial agent among the serotypes indicated (a negative association with resistance).
aOnly statistically significant associations, as measured by a two-tailed Fisher exact test with false discovery rate correction <0.05, are indicated.
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although these occurred a year later than the
change in serotypes documented in children.
Asymptomatic nasopharyngeal carriage of
S. pneumoniae by young children is frequently
assumed to be the main reservoir of this bacte-
rium, and vaccination has already been shown to
interfere with this process, although in Portugal
this did not lead to an overall decrease in the
prevalence of colonization [26]. The recurrent
transmission of bacteria from children to adults is
supported by the observation that the frequency
of nasopharyngeal carriage is higher in adults
with young children than in other adults [27],
suggesting that a significant fraction of the bac-
teria circulating among the adult population
originates in children. If that is so, it would be
expected that the effect observed in the adult
population would be delayed with respect to that
in children, as documented here.
These changes in serotype distribution in inva-
sive infections, which included the decrease in the
proportion of vaccine serotypes 4, 6B, 14 and 23F,
were accompanied by a significant increase in the
proportion of two non-vaccine serotypes, 19A and
7F, of which only serotype 19A was significant in
both children and adults. A post-vaccination
increase in the proportion of invasive infections
caused by serotype 7F among adults is so far
unique to Portugal, whereas increases in all age
groups of serotype 19A were also noted in several
studies in the USA [8,9] and were similarly
associated with multidrug resistance. For reasons
that remain unclear, serotype 5 showed a reduc-
tion in cRR of infection as compared to baseline in
adults in this study. Although these changes
occurred at the same time that PCV7 was intro-
duced in Portugal, and may therefore have been
triggered by vaccination, the possibility that the
higher yearly recovery of isolates in this survey
may also have influenced serotype distribution
cannot be excluded.
One of the beneficial outcomes of vaccination in
the USA was the reduction of the disease burden
associated with antibiotic-resistant pneumococci
[7]. In agreement with these findings, the fraction
of penicillin-non-susceptible pneumococci caus-
ing invasive infections in Portugal decreased in
children, but this benefit was not extended to the
adult population. In fact, in contrast to results
from the USA [7], the fraction of tetracycline-
resistant and erythromycin-resistant pneumococci
causing infections in the adult population and of
isolates simultaneously non-susceptible to peni-
cillin and resistant to erythromycin increased
relative to the baseline. These changes are related
to an increase in the importance of serotype 19A,
composed mainly of multidrug-resistant isolates
(Table 3), and to the reduction of serotypes
included in PCV7, namely serotypes 9V and
23F, that were found to be significantly associated
with non-susceptibility to penicillin, but not
simultaneously with resistance to erythromycin.
In contrast, serotype 7F isolates, which were
increasing in frequency exclusively in the adult
population, were fully susceptible to all antimi-
crobial agents tested. In spite of recent reports
detailing the emergence of resistance among non-
vaccine serotypes, traditionally associated with
susceptible isolates [28], and a general increase in
resistance in non-vaccine serotypes found in other
studies [29], an expansion of the proportion of
resistant isolates could not be shown in any
particular serotype in this study.
It has been suggested that local variations in
selection pressure are the best predictor of the
proportion of pneumococci resistant to b-lactams
and macrolides [30]. In agreement with this
suggestion, the high prevalence of penicillin-
non-susceptible and erythromycin-resistant iso-
lates observed in Portugal is paralleled by the fact
that Portugal is the second largest consumer of
b-lactams and the fifth largest consumer of macro-
lides in Europe [31]. The model of McCormick
et al. predicts a decrease in the prevalence of
penicillin-non-susceptible isolates and an overall
increase in erythromycin resistance, accompanied
by an increase in the prevalence of isolates that
are simultaneously penicillin-non-susceptible and
erythromycin-resistant [30]. This model fits the
data available from several European countries
participating in the European Antimicrobial
Resistance Surveillance System (EARSS) project
[32]. As the data analyzed included isolates up to
2002, they probably do not reflect vaccination,
and the changes must be attributed to antimicro-
bial use. With this in mind, the strikingly
increased importance of serotype 19A among
both children and adults could not only have
resulted from vaccine pressure but may have
been accelerated or compounded by shifting
trends in antimicrobial use before vaccination.
Variations in the importance of the various
serotypes in pneumococcal invasive infections
have also been noted [33], and alterations in these
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secular trends may have also influenced the
magnitude of the changes described here.
The reasons behind the higher rate of isolate
recovery in this study may be multifactorial, and
their impact on serotype distribution is difficult to
evaluate. On the whole, the data reported here
suggest that the use of the conjugate seven-valent
vaccine, even substantially below universal cov-
erage such as is currently the case in some
European countries, greatly reduced the propor-
tion of invasive infections due to vaccine sero-
types and resulted in significant beneficial
indirect effects on the serotype distribution of
pneumococci causing infections in adults. In
contrast to the USA, but in agreement with
previous studies of carriage in Portugal [26], a
universal reduction in the proportions of
infections caused by resistant pneumococci was
not shown. These data highlight the importance
of the local dynamics of the serotypes of pneumo-
cocci causing invasive infections in determining
the momentum and characteristics of the replace-
ment serotypes.
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